Mechanisms of Neuroprotection by Protein Disulphide Isomerase in Amyotrophic Lateral Sclerosis by Walker, Adam K. & Atkin, Julie D.
Hindawi Publishing Corporation
Neurology Research International
Volume 2011, Article ID 317340, 7 pages
doi:10.1155/2011/317340
Review Article
Mechanisms ofNeuroprotection by Protein Disulphide
IsomeraseinAmyotrophic LateralSclerosis
Adam K. Walker1,2 andJulieD. Atkin1,2
1Department of Biochemistry, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC 3086, Australia
2Howard Florey Institute, Florey Neuroscience Institutes and Centre for Neuroscience, The University of Melbourne, Parkville,
VIC 3010, Australia
Correspondence should be addressed to Adam K. Walker, adam.walker@latrobe.edu.au
Received 15 November 2010; Accepted 20 February 2011
Academic Editor: Changiz Geula
Copyright © 2011 A. K. Walker and J. D. Atkin.Thisisanopenaccess articledistributed under theCreative CommonsAttribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterised by the progressive loss of motor
neurons, leading to paralysis and death within several years of onset. Although protein misfolding is a key feature of ALS, the
upstream triggers of disease remain elusive. Recently, endoplasmic reticulum (ER) stress was identiﬁed as an early and central
feature inALS diseasemodels aswellasinhumanpatienttissues,indicatingthatER stresscould be animportantprocess indisease
pathogenesis. One important chaperone induced by ER stress is protein disulphide isomerase (PDI), which is both upregulated
and posttranslationally inhibited by S-nitrosylation in ALS. In this paper, we present evidence from studies of genetics, model
organisms,and patient tissues which indicate an active role for PDI and ER stress in ALS disease processes.
1.Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal, rapidly pro-
gressing neurodegenerative disorder primarily aﬀecting
motor neurons of the spinal cord, brainstem, and cortex [1].
The disease is characterised by muscle weakness leading to
paralysis and death usually within several years of diagnosis
[2]. Similar to other neurodegenerative diseases, protein
misfolding and abnormal intracellular protein inclusions
are pathological hallmarks of ALS. However, the pathogenic
mechanisms of disease are yet to be elucidated [3]. Approx-
imately 10% of ALS cases are inherited, and up to 20%
of these familial cases are caused by mutations in the
gene encoding superoxide dismutase 1 (SOD1) [4, 5].
SOD1-linked disease remains the most studied and best
characterised form of ALS, although successful therapeutic
interventionsfrom mutant SOD1models have thusfar failed
to translate to patients [1]. Additional factors involved in
disease have recently been identiﬁed, including the proteins
TAR DNA binding protein 43 (TDP-43) and fused in
sarcoma (FUS) as key players in disease pathogenesis [6],
and understanding the molecular mechanisms of ALS will
allowthedesignofeﬀectivetherapeuticsinthefuture.Recent
evidence has identiﬁed endoplasmic reticulum (ER) stress
andin particularthechaperoneproteindisulphideisomerase
(PDI), as important in ALS disease processes [7, 8]. The role
of PDI as a protective factor in ALS, with a particular focus
on disulphide bond-mediated SOD1 misfolding, forms the
central topic of this paper.
2.EndoplasmicReticulumStress
The ER is an important organelle for the folding and post-
translational modiﬁcation of many proteins, and it also
acts as a signiﬁcant intracellular calcium store [9]. The ER
forms close associations with other organelles, including
mitochondria, the Golgi apparatus and the nucleus, and
is therefore a central player in cell physiology [10, 11].
Since there is a high rate of protein production in the ER,
prevention of protein misfolding is an important function
of this organelle. The protein folding capacity of the ER
is adjusted according to requirements in order to maintain
homeostasis [12].2 Neurology Research International
Proteins misfold as part of normal physiology, and when
the rate of protein synthesis is increased, the burden of
unfolded proteins in the ER also increases. This results in ER
stress, which triggers signalling pathways collectively known
asthe unfolded proteinresponse (UPR)[13].Cellularinsults
including dysregulation of calcium stores, changes in the
ER redox state, nutrient deprivation as well as disturbances
in the Golgi, endosomal and vesicular transport systems,
and induction of mitochondrial-associated apoptosis, can all
elicit ER stress [14–16].
The UPR is a homeostatic mechanism which is initially
protective by upregulation of chaperone proteins such as
PDI,inhibition of generalprotein translation, and expansion
of ER volume. The UPR is mediated by activation of three
upstreamsensors ofERstress, namely,PKR-likeendoplasmic
reticulumkinase (PERK),inositol-requiring kinase 1 (IRE1),
and activating transcription factor 6 (ATF6) [17–21]. In the
basal state, immunoglobulin binding protein (BiP) is bound
totheupstreamsensors, which maintainstheminaninactive
state. Upon ER stress induction, BiP dissociates from PERK,
IRE1and ATF6 to preferentially bind hydrophobicregions of
the accumulating misfolded proteins, thereby activating the
upstream sensors [13]. PERK activation leads to phospho-
rylation of eukaryotic translation initiation factor 2 subunit
α (eIF2α), which attenuates general translation initiation, as
well as upregulation of ER stress-speciﬁc proteins including
activating transcriptionfactor4(ATF4)[12].IRE1activation
allows splicing of the mRNA of X box-binding protein 1
(XBP1), which is another ER stress-speciﬁc transcription
factor, and activates the c-Jun N-terminal kinase (JNK)
pathway,which leadsto ER volumeexpansion [22, 23]. ATF6
is transported to the Golgi apparatus following release from
BiP, where it is speciﬁcally cleaved to produce an additional
ER stress-speciﬁc transcription factor [9, 22].
Prolonged ER stress, as occurs in ALS, causes cell death
via apoptotic signalling. ER stress-activated apoptosis is
mediated in part by the release of Ca2+ from the ER and
upregulation of proapoptotic factors, including CCAAT/
enhancer binding protein-(C/EBP-) homologous protein
(CHOP), as well as activation of ER stress-speciﬁc caspases
[24, 25].
3.ERStressinALS
ER stress is induced in many diseases, such as diabetes,
tumour development, hypercholesterolemia and autoim-
mune disorders, and by viral infection [26]. Many neuronal
disorders also have ER stress as a component, including
Huntington’s disease [27, 28], HIV-associated dementia
[29], Alzheimer’s disease [30], Parkinson’s disease [31, 32],
Creutzfeldt-Jacob disease [33]a n dP i c k ’ sd i s e a s e[ 34]. In
addition, aging inhibits the early protective responses of ER
stress [35].
In ALS, PDI is one of the most upregulated proteins
in the spinal cords of presymptomatic transgenic SOD1G93A
rats and mice, which are the most commonly used animal
models of disease [7, 36]. Additionally, activation of the
full UPR occurs prior to symptom onset in these animals,
indicating an active role for ER stress in pathogenesis [7].
Indeed, ER stress occurs speciﬁcally in the vulnerable fast-
fatiguablemotorneuronspriortoactivationofotherdisease-
associatedmechanisms [37].ERstress alsooccursinsporadic
ALS patient spinal cord tissues, indicating that these ﬁndings
are not conﬁned to mutant SOD1 models of disease [38, 39].
Recent genetic studies have conﬁrmed the importance
of ER stress in ALS. Genetic ablation of Ask1, a target of
IRE1, or Puma, an ER-stress-related BH3-only protein, both
decrease UPR activation and slow disease in SOD1G93A mice
[40, 41]. Ablation of Xbp1, a key modulator of the UPR,
stimulated macroautophagy in motor neurons, delaying
disease onset and increasing survival of SOD1G86R mice [42].
Furthermore, administration of salubrinal, a small molecule
inhibitor of ER stress, to SOD1G93A mice signiﬁcantly
delayed disease progression [37]. These studies indicate
that modulation of ER stress could be potentially useful
in therapy for ALS patients, although further investigation
of the mechanisms of protection and design of targeted
molecules is required.
4.ProteinDisulphideIsomerase
Protein disulphide isomerase (PDI) is an important chaper-
one induced by ER stress which is involved in the formation,
reduction and isomerisation of disulphide bonds in protein
substrates. PDI is therefore an important cellular defence
against protein misfolding [43]. Recently, PDI upregulation
was detected in both mutant SOD1 transgenic rodent and
human ALS patient spinal cord tissues, suggesting that
PDI could act as a protective molecule in disease [7, 38].
PDI expression is also induced in other neurodegenerative
diseases such as Parkinson’s and Alzheimer’s diseases [30,
31], suggesting that PDI has a broad role in neurological
disorders related to protein aggregation.
5. The Structureand Expression of PDI
Thereareatleast19membersofthehumanPDIproteinfam-
ily, all of which possess at least one thioredoxin-like domain
and an ER targeting sequence [44]. Full-length PDI has
two thioredoxin-like domains which both contain a CGHC
dicysteine active site motif (termed the a and a  domains),
two intervening homologous domains (b and b
 ), with an x-
linker region, and a C-terminal c domain containing a KDEL
ER-retention motif which is also potentially involved in Ca2+
binding [45]. Mutagenesis studies identiﬁed the b
  domain
of PDI as the principal substrate-binding site, however other
domains also contribute to the binding of proteins [46]. The
CGHC motifs of the a and a  domain active sites cooperate
in forming disulphide bonds, although each motif possesses
independent enzymatic activity in the full-length protein
[47].
Many PDI family members have not been fully char-
acterised in terms of structure and function, although it
is becoming increasingly recognised that each member has
distinct substrate speciﬁcities [48, 49]. For example, whereas
PDI interacts with both glycosylated and nonglycosylatedNeurology Research International 3
proteins, ERp57 (also known as PDIA3 or Grp58) interacts
speciﬁcally with glycosylated proteins [50]. Also, while
ERp57−/− mice are nonviable [51], genetic ablation of either
of the PDI family members AGR2/Hag2 or ERdj5 produces
viable mice, with speciﬁc defects in mucin production and
salivary gland function, respectively, and increased ER stress
inaﬀectedtissues[52,53].NomodelsofgeneticPDIablation
in higher eukaryotes have been reported, although PDI is
essential in yeast [54]. Due to its widespread distribution
and important cellular functions, genetic ablation of PDI in
mammals would also likely be lethal. However, the potential
for redundancy with the other PDI family members remains
undetermined, and delineation of the diﬀerent roles and
substrate speciﬁcities of the PDI family members is an
important area for future research [48].
6.The FunctionsofPDI
PDI is primarily a disulphide bond-modulating chaper-
one, however PDI also facilitates ER-associated degrada-
tion of misfolded proteins [55] ,a n di si n v o l v e di nr e t r o -
translocation of misfolded cholera toxin from the ER to
the cytoplasm by interaction with the ER transmembrane
protein Derlin-1 [56, 57]. Other PDI family members are
involved in calcium homeostasis and antigen presentation
[44], while PDI is important for the cellular export of some
proteins, such as thyroglobulin [58].
PDI protects against aggregation of misfolded proteins
inseveralneurodegenerativediseases.PDIdecreasesaggrega-
tionoftheParkinson’s disease-associated synphilin-1 protein
in neuroblastoma cells, an activity which is dependent on
the presence of the CGHC active site motifs [59]. PDI
also prevents aggregation of α-synuclein in cell-free in
vitro systems [60], and ERp57 prevents aggregation and
subsequent neurotoxicity of prion protein in cell culture
[33]. PDI colocalises with ubiquitin-positive inclusions of
torsin-A in a transgenic mouse model of dystonia [61], and
with neuroﬁbrillary tangles in Alzheimer’s disease patient
brain tissue [62]. Furthermore, PDI prevents neuronal and
cardiomyocytecell deathcausedby hypoxia-ischaemia incell
culture and in rodent models, at least partly by decreasing
protein misfolding [63, 64]. In contrast to these ﬁndings,
PDI does not decrease the number of inclusions formed
by the variant of α1-antitrypsin linked with liver disease
[65], indicating some disease and protein-speciﬁcity of PDI
protection.
7.SubcellularLocalisationofPDI
While PDI is conventionally considered as an ER lumenal
protein,PDIhasalsobeendetectedinthenucleus,extracellu-
lar matrix and on the cell surface, where it modulates several
diﬀerent functions [8, 66–72]. Cell surface PDI facilitates
infection of HeLa cells by mouse polyoma virus [67],
modulates thrombus formation on the surface of platelets
[68] and facilitates dengue virus infection [73]. In addition,
both PDI and ERp57 interact with misfolded prion protein
on the cell surface, which could be important for prion
accumulation and cell-to-cell transmission [74]. Also, ER
stress can lead to the leakage of PDI to the cytoplasm [75].
These ﬁndings clearly indicate that PDI is found in other
cellular locations under a variety of diﬀerent conditions.
8.The Involvement of PDIinALS
PDI is upregulated in the spinal cords of SOD1G93A trans-
genic mice and rats at the pre-symptomatic, symptomatic
and end stages of disease [7, 38, 76, 77]. In addition, PDI
levels are increased in spinal cords of sporadic ALS patients
comparedtononneurologicalcontrols[38,39].Interestingly,
PDIcolocateswithinclusionsinmotorneuronsofSOD1G93A
mice [7], in human ALS patients [38], and also with
inclusions formed by vesicle associated membrane protein-
associated protein B (VAPB) in a Drosophila melanogaster
model of a rare familial form of ALScaused by mutant VAPB
[78]. These ﬁndings suggest that PDI is both upregulated
in disease and recruited to areas of the cell containing
aggregated protein. Furthermore, increased levels of PDI are
detected in the cerebrospinal ﬂuid (CSF) of ALS patients
compared to nonneurological controls, suggesting that the
level of PDI in CSF could be used as a potential biomarker of
disease [38].
These studies indicate an important function for PDI
in protection against mutant protein aggregation in ALS.
This is supported by the increase in inclusion formation
observed when mutant SOD1 expressing motor neuron-
like NSC-34 cells were treated with the broad disulphide
isomerase inhibitor bacitracin [7]. More recently, siRNA-
mediated knockdown of PDI was also shown to increase
mutant SOD1 inclusion formation in neuroblastoma cells,
conﬁrming the importance of PDI in modulating mutant
SOD1 aggregation [8]. Furthermore, overexpression of PDI
in neuroblastoma cells decreased the levels of insoluble
mutant SOD1, inhibited inclusion formation and decreased
apoptotic cell death [8]. Interestingly, a small molecular
mimic of the PDI active site also decreased mutant SOD1
aggregation and inclusion formation, indicating that similar
molecules may be beneﬁcial for treatment of disease [8].
Further investigation of the eﬀects of PDI mimics in animal
models of ALS is therefore warranted.
The ﬁndings of upregulation of PDI in disease and the
converse ﬁnding that overexpression is protective against
mutant SOD1 in cell culture raised the question of why the
increased levels of PDI in ALS were not beneﬁcial. Recently,
posttranslational modiﬁcation of PDI by S-nitrosylation of
critical active site cysteine residues, leading to inhibition of
PDI enzymatic activity, was identiﬁed in Parkinson’s and
Alzheimer’s disease brain tissues [59]. This same process of
S-nitrosylation of PDI has now been conﬁrmed to occur
in spinal cord tissues of sporadic ALS patients as well as
in transgenic SOD1G93A mice, and could explain a loss of
protection by PDI in disease [8]. S-nitrosylation involves the
covalent addition of nitrogen monoxide (NO) to thiol side
chains of cysteine residues of proteins, which can inﬂuence
many cellularprocessesbyalteringbothproteinfunctionand
protein-protein interactions [79]. S-nitrosylation can occur4 Neurology Research International
in a speciﬁc substrate-dependent manner, when one or a
few potential cysteine residues become modiﬁed. Nitrosative
stress caused by the accumulation of reactive nitrogen
species (RNS) such as peroxynitrite can cause aberrant S-
nitrosylation [80]. Nitrosative stress is linked with excessive
glutamate receptor activation, excitotoxicity and oxidative
stress [80, 81], processes which are key events in neur-
odegenerative diseases including ALS [82]. Recently, the
toxicity of mutant SOD1 in neuroblastoma cells has been
linked with increased levels of nitric oxide [83].
In addition to the ﬁndings of S-nitrosylation of protein
cysteine residues in ALS, a dramatic increase in tyrosine-
nitrated proteins in the insoluble fractions of spinal cords
frombothSOD1G93A mice and ALSpatients was identiﬁedin
a recent proteomic screen [84]. PDI was one of the nitrated
proteins increased in the insoluble protein fraction from
SOD1G93A mice, suggesting that nitrosative stress could also
lead to tyrosine nitration of PDI in ALS [84]. Previously,
the PDI family member ERp57 was found to be nitrated on
tyrosine residues in SOD1G93A mice [85].
Importantly, a speciﬁc mechanism for subcellular redis-
tribution of PDI has recently been identiﬁed in ALS [86,
87]. Several diﬀerent members of the reticulon family of
integralERmembraneproteinswereshown tomodulatePDI
distribution and reticulon overexpression caused a change
in localisation of PDI from a normal ER distribution to a
less homogenous punctate pattern [86]. In SOD1G93A mice,
deletion of the gene encoding the reticulon-4A,B proteins
accelerated disease processes, possibly by preventing the
reticulon-mediatedPDIredistribution[86].Theexactmech-
anism of the selective redistribution of PDI by reticulons
remains to be determined, and how this mechanism is pro-
tective in disease remains unknown, although it is possible
that redistribution allows selective interaction with a subset
of PDI target proteins [87]. Although the levels of PDI are
increased in the cerebrospinal ﬂuid of transgenic SOD1G93A
rats and ALS patients compared to controls [38], a further
unanswered question is whether the levels of PDI in other
locations, such as on the cell surface or in the cytoplasm,
are also aﬀected in disease. Overall, these ﬁndings indicate
that several diﬀerent processes, including posttranslational
modiﬁcations and subcellular redistribution, are involved in
modifying PDI function in ALS, with potential implications
for disease pathogenesis.
9.Conclusion
The recent identiﬁcation of ER stress as a central process
involved in ALS, and the particular involvement of PDI as a
protective factor in disease, highlights new areas of research
which could have potential therapeutic application. Both ER
stress and PDI S-nitrosylation occur not only in mutant
SOD1-linkeddisease, butalso in the more common sporadic
forms, indicating that targeting these pathways could be
useful in all forms of ALS. Additionally, pharmacological
prevention of protein misfolding, stimulation of autophagy
orinhibition of oxidative stress could also decrease ER stress,
and may be beneﬁcial in disease. Possible applications of
this research include development of small molecule PDI
mimics or ER stress inhibitors, which could prove beneﬁcial
in treating this devastating disease.
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